The following cardiovascular trials were open at Baylor Scott & White The Heart Group in 2015. This list is preserved from the practice’s archived website and is historical — it does not reflect currently enrolling studies. Speak with your cardiologist about trials that may be open today.
Pioneer II
The Pioneer II study is an open-label, tandomized, controlled, multicenter study exploring two treatment strategies of Rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention: PIONEER AF-PCI.
Sur-TAVI
Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement.
PVL in TAVR
A Novel Imaging Approach to Assess Paravalvular Leak for Transcatheter Valve Replacement.
Low Dose CT
A Novel Low-dose-contrast Cardiac Computed Tomography Method for Pre-Procedural Guidance in Transcatheter Aortic Valve Replacement.
ABSORB
Resorbable coronary stent-Brown
ISCHEMIA
To determine the best management strategy for patients with stable ischemic heart disease (SIHD) and moderate-to-severe ischemia; routine early invasive strategy (INV) with cardiac catheterization (cath) followed by revascularization plus optimal medical therapy (OMT) is superior to a conservative strategy (CON) of OMT.
SYMPLICITY
Renal denervation for uncontrolled hypertension.
STOP AF PAS
Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)-Gopal
PARTNER II
Placement of Aortic Transcatheter Valves Trial. The Safety and Effectiveness of the SAPIEN XT™ Transcatheter Heart Valve with NovaFlex and Ascendra 2 delivery systems (Transfemoral and Transapical) in Intermediate Risk for Aortic Valve Surgery and Patients Who Cannot Undergo Surgery.
Resolute Integrity
A Clinical Evaluation of the Medtronic Endeavor® Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries with a Reference Vessel Diameter of 2.25 mm to 4.2 mm
EXCEL
Evaluation of XIENCE PRIME or XIENCE V versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization.
COAPT
Clinical Outcomes Assessment of the MitraClip Percutaneous Therapy for High Surgical Risk Patients. EVOLVE II Trial: The purpose of this study is to assess the safety and effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 34 mm in length (by visual estimate) in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate). CTOT II Trial: is an investigative consortium for conducting clinical and associated mechanistic studies that will lead to improved outcomes for transplant recipients. The purpose of these studies is to improve short and long-term graft and patient survival. PORTICO: is a prospective, multi-center, randomized-controlled clinical study, designed to evaluate the safety and effectiveness of the St. Jude Medical (SJM) Portico Transcatheter Heart Valve and Delivery Systems (Portico) via the transfemoral and transapical delivery methods, in high and extreme risk cohorts. Direct Flow: is a study to assess the safety and effectiveness of the Direct Flow Medical aortic valve system. This is for people with severe aortic stenosis who are not well enough to undergo a surgical repair.